KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biolife Solutions (BLFS) Other Non Operating Income (2021 - 2025)

Biolife Solutions (BLFS) has disclosed Other Non Operating Income for 5 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 1433.77% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 255.19% increase, with the full-year FY2025 number at $1.8 million, up 267.41% from a year prior.
  • Other Non Operating Income was $1.2 million for Q4 2025 at Biolife Solutions, up from $284000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.2 million in Q4 2025 to a low of -$22000.0 in Q2 2022.
  • A 5-year average of $252833.3 and a median of $244500.0 in 2023 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 2128.57% in 2022, then tumbled 78.12% in 2024.
  • Biolife Solutions' Other Non Operating Income stood at $296000.0 in 2021, then surged by 32.43% to $392000.0 in 2022, then crashed by 30.36% to $273000.0 in 2023, then crashed by 71.79% to $77000.0 in 2024, then skyrocketed by 1433.77% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Other Non Operating Income are $1.2 million (Q4 2025), $284000.0 (Q3 2025), and $247000.0 (Q2 2025).